NCT04282018 2026-02-20Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabBeOne MedicinesPhase 1/2 Completed97 enrolled 43 charts
NCT02795182 2022-07-01Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell MalignanciesBeiGenePhase 1 Completed75 enrolled 17 charts